Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Izrael, Tel Awiw
Ari Raphael
29 lat doświadczenia
akredytacje :
Akredytacje :
Zabieg NanoKnife w Izraelu kosztuje zazwyczaj od $18,500 do $31,500. Cena zależy od stopnia skomplikowania guza oraz wybranej placówki. Na koszt wpływa rodzaj leczonego narządu, liczba użytych elektrod oraz czas hospitalizacji. Pacjenci oszczędzają około 0% w porównaniu z Polską, gdzie średni koszt to $9,000. Standardowe pakiety w izraelskich szpitalach obejmują ablację, znieczulenie, badania krwi oraz obrazowanie specjalistyczne, w tym PET PSMA CT.
Opinia ekspercka Bookimed: Wybór multidyscyplinarnego ośrodka, jak Sourasky Medical Center (Ichilov), przynosi pacjentom onkologicznym wymierne korzyści. Pakiety NanoKnife zaczynają się tam od około 27 550 €, zapewniając 90% skuteczności leczenia. Szpital Ichilov posiada akredytację JCI i znajduje się na liście najlepszych szpitali świata według Newsweeka. Rocznie placówka wykonuje 34 000 operacji, co gwarantuje ogromne doświadczenie chirurgiczne. W złożonych przypadkach konsultacje z ekspertami, takimi jak profesor Jack Baniel, dają dostęp do światowej klasy badań urologicznych. Prywatne placówki, jak Assuta z cenami od około 38 700 €, stawiają na krótszy czas oczekiwania i indywidualne podejście w akredytowanym przez JCI środowisku.
Dlaczego warto rozważyć Izrael jako miejsce leczenia metodą nanoknife?
Skorzystaj z zaawansowanych rozwiązań NanoKnife w zaufanych klinikach .
| Izrael | Turcja | Austria | |
| Nano-nóż | od $18,500 | od $9,500 | od $25,000 |
Day 1 - Arrival
Day 2 - Pre-Operation
Day 3 - Pre-Operation
Day 4 - NanoKnife Procedure
Day 5 - Post-Operation
Week 1 - Rehabilitation
Week 2-4 - Rehabilitation
Week 5-6 - Rehabilitation
Please note that each patient"s recovery timeline may vary depending on their individual health condition, the size and location of the tumor, and their overall physical fitness. Always consult with your doctors and follow their advice for the best possible outcome.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Dr. Barak Rosenzweig, MD, directs the Urological Oncology Service at Sheba Medical Center. He is a uro-oncologic surgeon with nearly 20 years of experience. He treats complex urologic cancers with advanced robotic and minimally invasive methods. He is listed among Israel’s Best Doctors by Forbes.
Expertise includes tumors of the prostate, kidney, bladder, testis, and upper urinary tract. He performs robotic radical prostatectomy, kidney-sparing partial nephrectomy, and advanced laparoscopy. Diagnostics include MRI-guided fusion biopsy and imaging-based personalized planning.
He completed a Urological Oncology fellowship at Memorial Sloan Kettering Cancer Center. He is a Senior Physician in the Department of Urology and a Clinical Senior Lecturer at Tel Aviv University. He is a graduate of the Sheba Talpiot program. He is an active researcher with over 200 publications in urologic oncology.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.
Czołowy ekspert w dziedzinie technologii NanoKnife, koncentrujący się na nowotworach klatki piersiowej i innowacyjnym profilowaniu genomowym w Centrum Medycznym Sourasky.